{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:55:10Z","timestamp":1774918510409,"version":"3.50.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI147490"],"award-info":[{"award-number":["R01 AI147490"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 AI147490"],"award-info":[{"award-number":["R01 AI147490"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of California San Diego CFAR","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K01 AA027733"],"award-info":[{"award-number":["K01 AA027733"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA023356"],"award-info":[{"award-number":["T32 DA023356"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The Eliminate Hepatitis C San Diego County Initiative was established to provide a roadmap to reduce new HCV infections by 80% and HCV-related deaths by 65% by 2030. An estimate of the burden of HCV infections in San Diego County is necessary to inform planning and evaluation efforts. Our analysis was designed to estimate the HCV burden in San Diego County in 2018.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We synthesized data from the American Community Survey, Centers for Disease Control and Prevention, California Department of Public Health, Public Health Branch of California Correctional Health Care Services, San Diego Blood Bank, and published literature. Burden estimates were stratified by subgroup (people who inject drugs in the community [PWID], men who have sex with men in the community [MSM], general population in the community [stratified by age and sex], and incarcerated individuals). To account for parameter uncertainty, 100,000 parameter sets were sampled from each parameter\u2019s uncertainty distribution, and used to calculate the mean and 95% confidence interval estimates of the number of HCV seropositive adults in San Diego in 2018.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Findings<\/jats:title>\n<jats:p>We found there were 55,354 (95% CI: 25,411\u201393,329) adults with a history of HCV infection in San Diego County in 2018, corresponding to an HCV seroprevalence of 2.1% (95% CI: 1.1\u20133.4%). Over 40% of HCV infections were among the general population aged 55\u201374 and one-third were among PWID.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study found that the largest share of infections was among adults aged 55\u201374, indicating the importance of surveillance, prevention, testing, and linkages to care in this group to reduce mortality. Further, programs prioritizing PWID for increased HCV testing and linkage to care are important for reducing new HCV infections.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0251635","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T18:10:11Z","timestamp":1623262211000},"page":"e0251635","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-3616","authenticated-orcid":true,"given":"Adriane","family":"Wynn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Tweeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma","family":"Wooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra L.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricris","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franchesca","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"VanWormer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Suckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian B.","family":"Ramers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"pone.0251635.ref001","unstructured":"Centers for Disease Control and Prevention. CDC Estimates Nearly 2.4 Million Americans Living with Hepatitis C 2018 [Available from: https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2018\/hepatitis-c-prevalence-estimates-press-release.html."},{"key":"pone.0251635.ref002","unstructured":"Centers for Disease Control and Prevention. Hepatitis C Kills More Americans than Any Other Infectious Disease. 2016 [Available from: https:\/\/www.cdc.gov\/media\/releases\/2016\/p0504-hepc-mortality.html."},{"issue":"3","key":"pone.0251635.ref003","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"J Grebely","year":"2018","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"pone.0251635.ref004","unstructured":"The National Academies of Sciences E, Medicine,. A National Strategy on the Elimination of Hepatitis B & C: Phase Two Report Release. Accessed from: http:\/\/wwwnationalacademiesorg\/hmd\/Activities\/PublicHealth\/NationalStrategyfortheEliminationofHepatitisBandC\/2017-MAR-28aspx. 2017."},{"key":"pone.0251635.ref005","unstructured":"World Health Organization. Advocacy brief: Combating hepatitis B and C to reach elimination by 2030. Accessed from: https:\/\/wwwwhoint\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/. 2016."},{"key":"pone.0251635.ref006","volume-title":"Age and Sex: 2018 American Community Survey 1-Year Estimates","author":"United States Census Bureau\/American Fact Finder","year":"2018"},{"issue":"Rr-4","key":"pone.0251635.ref007","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u00b11965","volume":"61","author":"B Smith","year":"2012","journal-title":"MMWR Recommendations and reports"},{"key":"pone.0251635.ref008","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report 2018\u2014Hepatitis C. 2020."},{"issue":"6","key":"pone.0251635.ref009","doi-asserted-by":"crossref","first-page":"e64789","DOI":"10.1371\/journal.pone.0064789","article-title":"Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992\u20132007","volume":"8","author":"B Tempalski","year":"2013","journal-title":"PLoS One"},{"key":"pone.0251635.ref010","volume-title":"HIV Infection, Prevention, and Health Behaviors Among People Who Inject Drugs (PWID)","author":"National HIV Behavioral Surveillance (NHBS)","year":"2018"},{"issue":"1","key":"pone.0251635.ref011","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.2196\/publichealth.5365","article-title":"Estimating the Population Sizes of Men Who Have Sex With Men in US States and Counties Using Data From the American Community Survey","volume":"2","author":"JA Grey","year":"2016","journal-title":"JMIR public health and surveillance"},{"issue":"4","key":"pone.0251635.ref012","doi-asserted-by":"crossref","first-page":"e0195575","DOI":"10.1371\/journal.pone.0195575","article-title":"Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination","volume":"13","author":"SN Facente","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"pone.0251635.ref013","doi-asserted-by":"crossref","first-page":"ofz160","DOI":"10.1093\/ofid\/ofz160","article-title":"Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000\u20132015","volume":"6","author":"A Chaillon","year":"2019","journal-title":"Open forum infectious diseases"},{"issue":"9","key":"pone.0251635.ref014","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/j.1537-2995.2011.03270.x","article-title":"The healthy donor effect: a matter of selection bias and confounding","volume":"51","author":"F Atsma","year":"2011","journal-title":"Transfusion"},{"key":"pone.0251635.ref015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugpo.2017.06.006","article-title":"Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California","volume":"47","author":"D Horyniak","year":"2017","journal-title":"The International journal on drug policy"},{"issue":"Suppl 2","key":"pone.0251635.ref016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/00333549071220S212","article-title":"Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs","volume":"122","author":"J Buffington","year":"2007","journal-title":"Public health reports (Washington, DC: 1974)"},{"issue":"7","key":"pone.0251635.ref017","doi-asserted-by":"crossref","first-page":"e102883","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"ER Cachay","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"pone.0251635.ref018","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013\u20132016","volume":"69","author":"MG Hofmeister","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"pone.0251635.ref019","doi-asserted-by":"crossref","first-page":"e101554","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","volume":"9","author":"BR Yehia","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pone.0251635.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC Recommendations for Hepatitis C Screening Among Adults\u2014United States, 2020","volume":"69","author":"S Schillie","year":"2020","journal-title":"MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports"},{"issue":"9","key":"pone.0251635.ref021","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S2468-1253(20)30238-7","article-title":"The impact of COVID-19 on hepatitis elimination","volume":"5","author":"C Wingrove","year":"2020","journal-title":"The lancet Gastroenterology & hepatology"},{"issue":"Suppl 2","key":"pone.0251635.ref022","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"NK Martin","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0251635.ref023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"A Trickey","year":"2019","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"pone.0251635.ref024","first-page":"Cd012021","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"L Platt","year":"2017","journal-title":"The Cochrane database of systematic reviews"},{"issue":"1","key":"pone.0251635.ref025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/add.13948","article-title":"Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic","volume":"113","author":"H Fraser","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"issue":"1","key":"pone.0251635.ref026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"JM Micallef","year":"2006","journal-title":"Journal of viral hepatitis"},{"issue":"1","key":"pone.0251635.ref027","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12879-016-1807-5","article-title":"Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis","volume":"16","author":"DJ Smith","year":"2016","journal-title":"BMC infectious diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T18:10:42Z","timestamp":1623262242000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251635"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0251635","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]}}}